The EYES have it, Early Stage Detection of Diabetes and Cardiovascular Disease

Using Artificial Intelligence (AI) to better image and analyze the retina of the eye to detect early stage disease is a potential game changer in the prevention of blindness and cardiovascular diseases such as stroke, heart attack, and diabetic related disease.

Today’s company is pioneering its work in this field with USA clinical trials commencing soon and a global commercialization rollout already underway. The company is Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) (“DIAGNOS”).

DIAGNOS has developed an Artificial Intelligence (AI) tele-ophthalmology platform, which uses Computer Assisted Retina Analysis (CARA) to examine a patient’s retina (back of the eye) for the early detection of diseases, such as diabetes, and conditions such as cardiovascular disease, hypertension and stroke. CARA’s image enhancement algorithms provide sharper, clearer and, thus, easier-to-analyze retinal images.

CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia). DIAGNOS already operates in 16 countries, with 131 screening sites, has 222,034 patients under their care, and has performed more than 400,000 retinographies around the world. DIAGNOS’ CARA achieves great precision in diabetic retinopathy pre-diagnoses, reaching a sensitivity of 98.4%, specificity of 97.6% and a certainty of 97.9%.

DIAGNOS uses an AI technology know as CARA to better analyze the retina of the eye, a key way to detect early cardiovascular disease

Source: DIAGNOS website

DIAGNOS achieves two firsts and an eight at the GAMMA (Glaucoma grAding from Multi-Modality imAges) contest

At the recent GAMMA competition, DIAGNOS achieved some stunning results including two firsts and an eighth place out of a total of 566 teams. Now that’s super impressive!

The October 28, 2021 announcement stated: “DIAGNOS was the only one, of the top 8 teams, that competed with a marketed, commercialized system. DIAGNOS used the same platform that it currently uses for diabetic retinopathy screening, which is marketed worldwide, while the others were principally from academic institutions.”

Key results included:

  • Localization of macula fovea in fundus images. (DIAGNOS placed 1st overall)
  • Segmentation of optic disc and cup in fundus images(DIAGNOS placed 1st overall)
  • Grading glaucoma using multi-modality data. (DIAGNOS placed 8th overall)

USA clinical trial for the early detection and prevention of stroke using CARA-STROKE

On November 23 DIAGNOS announced: “DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of stroke using CARA-STROKE.” The trial aims to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke through the inspection and micro circulation analysis of the retina.

The upcoming USA clinic trial at the CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC, is intended to further prove the effectiveness of DIAGNOS’s CARA technology.

Note: CommonSpirit Health is a non-profit national Catholic healthcare system that operates 137 hospitals and more than 1,000 care sites across 21 states of the USA.

Some facts about cardiovascular disease including stroke

  • Stroke causes 1 out of every 20 deaths.
  • The management of stroke represents a cost of around US$34 billion per year in the United States.
  • According to the WHO, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
  • Europe averages approximately 650,000 stroke related deaths each year.
  • Worldwide Research Institutes says that the worldwide market size for stroke management will hit over $66 billion by 2023.

Source: DIAGNOS announcement

Clearly, the above facts speak volumes as to the need to diagnose cardiovascular disease early. And that is exactly what DIAGNOS does.

Not just an idea, commercialization has begun

As previously discussed in some detail here, DIAGNOS commercialization is gaining momentum. Some examples include:

  • July 22, 2021 – DIAGNOS announced the official opening of the AI Assisted screening clinic at Magrabi Hospital in Saudi Arabia. Magrabi Hospitals and Centers has thirty-four branches in the Middle East.
  • July 28, 2021 – DIAGNOS announced a pilot in Spain with three franchisees from Opticalia Group.
  • August 16, 2021 – DIAGNOS announced signing a Memorandum of Understanding (MoU) for a distribution agreement with Essilor International. Essilor International is the world’s leading ophthalmic optics company.
  • September 2, 2021 – DIAGNOS announced a three-year contract renewal with Optina Diagnostics providing a Telemedicine Platform to support their early detection of Alzheimer’s Disease.
  • September 14, 2021 – DIAGNOS announced a 3-year contract with Cielo Vista Eye Clinic in Mexico.
  • September 16, 2021 – DIAGNOS announced a multi-year contract with Juarez Health & Medical Tourism Cluster in Mexico, who focuses on medical tourism and serves between 10-12,000 patients a day.

Closing remarks

DIAGNOS’s CARA technology is clearly a winner. It has already won numerous global contracts and the recent GAMMA competition. Any potentially positive results from the upcoming CommonSpirit Health Research Institute clinical trial would just be icing on the cake.

With 15 million people suffering a stroke worldwide each year the time has come for better early diagnosis to allow earlier treatment and prevention, potentially reducing this terrible statistic.

Diagnos Inc. trades on a market cap of just C$30 million which seems very small when compared to the massive market for cardiovascular disease diagnosis. One to follow closely in the years ahead.

Happy Earth Day – Look to these Stock to Support Mother Earth and Boost Your Portfolio Performance

Investors are taking a deeper dive into corporations, looking beyond financial metrics and into a company’s Environmental, Social, and Governance (ESG) standards as a measure of its commitment to all stakeholders, including a healthier planet.

Last year, Laurence Fink, the Founder and CEO of BlackRock, the world’s largest asset manager, sent a letter to the CEOs of its invested companies and a second letter to its clients, addressing a focused mandate on sustainable investing. BlackRock sees climate risk as investment risk and plans to act ahead of the serious impacts of climate change by doubling its number of ESG funds.

Below are four companies where ESG has become a critical part of their business or a core belief in building a more sustainable business environment.

1. Cielo Waste Solutions Corp. (CSE: CMC | OTCQB: CWSFF | FSE: C36)

Cielo is literally turning garbage into gas; it doesn’t get much greener than that!

Cielo, a waste to renewable fuel company, has a patented technology that converts landfill garbage into renewable high-grade diesel used in transport trucks and kerosene used for aviation jet and marine fuel.

After 16 years and C$75 million in research and development, and now a fully functional plant, Cielo is currently riding the “green wave” of investor interest in environmental tech, and the stock price has responded accordingly, up over 1,000% year-to-date.

Cielo is currently rolling out 10 facilities in North America over the next couple of years but with revenues expected from its first plant this year.

Read the latest story about Cielo here.

2. mCloud Technologies Corp. (TSXV: MCLD | OTCQB: MCLDF)

mCloud helps businesses reduce energy waste, maximize energy production and get the most out of critical energy infrastructure. It focuses on using Artificial Intelligence (AI) to curb energy waste in buildings, maximize the energy production of wind turbines and extend the lifespan of critical energy infrastructure in a variety of different industries.

mCloud recently rolled out a new service that detects the leakage of gases during oil and gas production that will drive major carbon emission reductions for its customers in Alberta and the Middle East.

And yesterday, mCloud announced a partnership with three North American energy utility providers to offer its energy-saving solutions for HVAC and improved indoor air quality (IAQ) monitoring solutions that could target over one million commercial buildings in the U.S. and Canada.

Read about yesterday’s news release here.

3. Nano One Materials Corp. (TSXV: NNO)

Nano One Materials is a technology company with a patented and scalable industrial process for the production of low-cost, high-performance cathode materials used in lithium-ion batteries.

The cathode determines the battery’s capacity and voltage, and can comprise 20% or more of the costs of a lithium-ion battery.

Nano One’s proprietary “One Pot” furnace process creates a coated single crystal powder that protects the cathode from side reactions while allowing the transfer of lithium ions between electrolyte and cathode.

And, importantly, the process addresses ESG concerns around energy, waste, and carbon footprint in the lithium-ion battery supply chain. It is an environmentally friendly process using limited water, and as it eliminates intermediate steps, it eliminates expensive and energy-intensive metal conversions and does not have a hazardous waste stream.

See the latest video about Nano One Materials here.

4. Neo Lithium Corp. (TSXV: NLC | OTCQX: NTTHF)

Neo Lithium is advancing its 100% owned Tres Quebradas (3Q) project, a high-grade lithium brine lake and salar complex in Argentina. The 3Q Project is located in Latin America’s “Lithium Triangle” and covers 350 KM2 (~86,500 acres) in the largest lithium-producing area in Argentina.

Last week, Neo Lithium announced that it engaged Golder Associates and the Argentinean National University of San Martin, to help with the ESG program as part of its Feasibility Study for 3Q project.

Waldo Perez, CEO of Neo Lithium said, “We take very seriously our compromise with all of our stakeholders and future generations, which in large part includes all aspects of ESG.”

Neo Lithium wants to be at the low end of the CO2 emission footprint when compared with other lithium brine projects.

Read the latest story about Neo Lithium here.

 Happy Earth Day, Do Something Nice for Mother Earth.

Predictiv AI – Using Artificial Intelligence to Solve “Real World” Problems

Predictiv AI’s ThermalPass Part of a Back-to-Work Strategy

The U.S. Centers for Disease Control and Prevention (CDC) reported on Wednesday that approximately 123.9 million people in the U.S. have received at least one dose of a COVID-19 vaccine, representing about 37.3% of the total population.

While vaccination rates are increasing and new COVID-19 cases begin to decline, corporations are developing return-to-the-office strategies that address employees’ safety expectations that include regular health and temperature checks.

Temperature Checks Part of the New Workplace Health & Safety Protocols

In order to avoid admitting employees with symptoms, buildings are employing screening measures including restricting entry to a single access point to facilitate temperature checks.

To reduce lineups and wait times, buildings are implementing fast methods of fever detection, and ThermalPass by Predictiv AI Inc. (TSXV: PAI) is one solution.

ThermalPass Fever Detection System

Last year, Predictiv AI launched ThermalPass, a fever-detection system that instantly screens for higher than normal body temperatures that could be caused by a virus, such as COVID-19, in order to reduce the risk of spreading the contagion.

The ThermalPass stand-alone unit enhances public safety by providing fast, touch-free scanning of people at entranceways of high-traffic, public locations, and its waterproof design allows for both indoor and outdoor uses.

By integrating 24 medical-grade, non-invasive thermal sensors onto a metal frame, and taking 1200 readings per second, each unit can process one person per second and is perfect for mass screening applications at high-traffic locations such as airports, hospitals, office buildings, and sports stadiums.

Growing Sales and Resellers

This week, Predictiv AI reported that it signed F2 Factor to provide strategic support services to increase sales and distribution of ThermalPass.

This announcement follows a slew of partnerships signed earlier this year with other resellers including TFG Concepts (TFG), MCL Sustainable Cleaning Solutions (MCL), and Security Identification Systems Corp. (SISCO).

  • TFG is a sales agency with more than 30 years of experience representing manufactures and brands and has partnered before with companies such as Canadian Tire, Costco, Home Depot, and Lowes.
  • MCL plans to focus on the Education, Food Service, and Government sectors across Canada and has almost four decades of experience as a master distributor and their customers include Air Canada, the City of Toronto, and Sunnybrook Hospital.
  • SISCO will integrate ThermalPass with its Fast-Pass® Visitor Management System to help with track-and-trace efforts for building occupants and visitors.

Last week, Predictiv AI announced that it has installed multiple ThermalPass temperature scanning devices in Memorial Healthcare System hospital facilities in Broward County, Florida.

Memorial Healthcare is a provider of healthcare services in south Florida through a six-hospital network and various ancillary facilities. By integrating ThermalPass, it has helped eliminate forehead temperature checks and captures core employees’ temperature in a more efficient manner.

Dawn de la Vega, Director of Nursing at Memorial Regional Hospital, stated, “With COVID-19 still threatening our community, it’s important for us to continue using technology in a way that will help us maximize our team’s time and provide quality and safe care to our community.”

Predictiv AI’s ThermalPass Adopted by Memorial Healthcare System

Predictiv AI's ThermalPass Adopted by Memorial Healthcare System


Predictiv AI – Using Artificial Intelligence to Solve “Real World” Problems

Predictiv AI is not a 1-product company but an innovator and strategic operator of emerging technology companies with a focus on artificial intelligence (AI), blockchain solutions, and the Internet-of-Things. The Company’s R&D division, AI Labs Inc. (AI Labs), develops new products that solve real-world problems.

In March, Predictiv AI announced that it partnered with the Waterloo Artificial Intelligence Institute (Waterloo.AI) at the University of Waterloo to allow AI Labs to pursue its AI reach and commercialization efforts and leverage Waterloo.AI as an extension of the Predictiv AI team.

Harold Godwin, Managing Director of Waterloo.AI, stated, “We are thrilled to have Predictiv AI join as a partner with Waterloo, this is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI.”

The collaboration will allow AI Labs to access the artificial intelligence resources at Waterloo.AI, increasing the bandwidth in ideation, research, and development of solutions for real-world problems.

Final Thoughts

Predictiv AI helps businesses and organizations make smarter decisions using AI, deep machine learning, and data science.

As AI continues to be a disruptive technology, investors are looking for ways to profit from it and Predictiv AI could be an avenue for an AI investment.

With a market capitalization of less than C$11 million, there is still plenty of upside to this Canadian high-tech company.

Warrant Exercise Builds Treasury for Perimeter’s 2021 Commercialization Efforts

Last week, Perimeter Medical Imaging AI, Inc. (TSXV: PINK) announced that approximately 2.35 million warrants subject to an accelerated expiry were exercised, resulting in cash proceeds to the company of over C$4.7 million.

Inclusive of the C$4.7 million raised from the exercise of accelerated warrants noted above, Perimeter received over C$7.28 million from the accelerated warrant exercise and can expect a further C$0.68 million if the remaining warrants are exercised by March 8.

The company plans to use the proceeds in its commercialization and development plans to bring Perimeter’s medical imaging solution to the market in 2021. Perimeter’s direct clinical sales efforts include a limited market release of the platform this quarter with a broader commercial launch in the second quarter.

Perimeter’s OTIS™ Platform

Perimeter is a medical technology company utilizing ultra-high-resolution, real-time, advanced imaging tools in cancer surgeries to improve patient outcomes and reduce costs in the healthcare system.

Perimeter’s OTIS™ platform, cleared by the FDA as an imaging tool, is a system that provides surgeons, radiologists, and pathologists with ultra-high-resolution, sub-surface image volumes to allow clinicians to visualize microscopic tissue structures during a clinical procedure.

The Problem Being Solved

According to Dr. Alastair Thompson, MD, a surgical oncologist and professor at Baylor, “One of the big problems in breast cancer surgery is that in about one in four women on whom we do a lumpectomy to remove cancer, we fail to get clear margins.

Therefore doctors are searching for an effective and user-friendly tool to help identify that the breast cancer has been removed from a woman’s breast.

Baylor is one of many institutions that is conducting a study with Perimeter’s medical imaging system for providing real-time, high-resolution images of the removed tissues to assist cancer surgeons in making better decisions during operations.

Hospitals see this type of system could lead to a large improvement in patient care and reduce the need for second surgeries.

Atlas AI Project – Artificial Intelligence (AI) / Machine Learning (ML) Tools

In addition, Perimeter is advancing its advanced AI/ML image assessment tools through clinical development through its Atlas AI project.

Backed by a $7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT), a leading state body that funds cancer research, the project will collect images of breast tumors from up to 400 patients for the purpose of training and testing Perimeter’s “ImgAssist” AI technology to increase the efficiency of image review.

AI and analytics are seen as a way to address the inefficiencies and challenges that current operating rooms are facing in identifying cancerous tissues. According to the company, currently 1 in 4 patients who receive a lumpectomy has to come back for a second operation because the surgeon did not remove all of the cancer cells.

Focus on Breast Cancer but Applications Beyond

Cancer continues to grow amongst the population and puts a burden on the healthcare system. According to the World Cancer Research Fund, breast cancer is the most common cancer in women worldwide, representing about 25 percent of all cancers in women.

In 2021, Breastcancer.org estimates that over 330,000 new cases of breast cancer are expected to be diagnosed in the United States and over 43,000 women are expected to die from breast cancer.

While currently focusing on deployments targeting breast cancer centers, OTIS™ has applications beyond breast cancer and into the larger multi-billion-dollar cancer surgery market.

Final Thoughts

According to a recent industry report from Markets and Markets, the Surgical Imaging Market is projected to grow from US$1.8 billion in 2020 and reach US$2.4 billion by 2025, growing by 6.3% annually.

One of the major factors driving the growth of this market includes the increasing demand for minimally invasive procedures that Perimeter’s platform addresses.

With the commercial launch of the product scheduled for this year, Perimeter has the potential to benefit from this growing market.

Perimeter Medical Device Platform


Safe Entry Stations offers real competition in the AI-driven remote sensing reality already for entry

“Hey Siri”

“Hey Google”

“Hey Alexa”

Have we missed anybody? Probably…. Yes, technology is watching you, but is that a good or a bad thing?

In the case of Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF), that’s the point and yes it is a good thing. As some of you know, the company “develops disruptive AI technologies for health and safety in workplaces and healthcare”. Translated – remote sensing and artificial intelligence (AI) solutions to protect our health.

The value of this technology should not be underestimated, necessity is the mother of invention. It’s a coronavirus world now and the virus (like the flu, like a cold etc.) isn’t going away anytime soon. The arrival of the virus and the global pandemic that followed means that there is now a serious focus on detection of early indicators of infected people. Detection will help stem the spread of the coronavirus and others.

Predictmedix is one of those companies which has an infectious disease screening solution. However, unlike the competitors, the company’s Safe Entry Station is head and shoulders above the competition. The fact that the company has Kapil Raval as its Advisory Board Chair should tell the market something – he is the Director of AI, Business Development, for Microsoft.

“Having a long-term sustainable product for better workplace health and safety” is how Dr. Rahul Kushwah, company COO described their vision. Their screening solutions are powered by AI and are designed to analyze seven different symptoms associated with the coronavirus, providing results in seconds. The system utilizes multispectral imaging with a focus on visual spectral imaging along with infrared thermography to identify individuals exhibiting symptoms associated with infectious diseases. The coronavirus detection system is commercial and is being deployed now.

The AI monitors and identifies potential presence of infectious disease symptoms such as fatigue, headache, coughing, sneezing, blood flow, sweat gland activation, metabolism, fever along with other key determinant factors. Sick or not sick.

The AI algorithms in their system are also continuously evolving via machine learning and should be able to detect, assess and determine the probability of that person being infected or not infected, even as the virus mutates. Sick or not sick.

So significant is this technology that the company already has partnerships in Canada, the US and India for system installation. A very significant customer is Indian Oil Corporation (IOC), where deployment is at the logistics stage – IOC has a workforce of more than 33,000 employees. There are several other deployments in the planning stage yet to be announced.

With a physical detection system, in addition to assessing virus conditions, the company can also utilize the AI for the detection of alcohol, cannabis and opioid intoxication. The company has a first-to-market cannabis AI detection system which is being expanded to analyze for other intoxicants. The system uses multispectral recognition technologies that capture data analyzed by the proprietary AI. This is especially important in environments where impairment could be considered a safety risk.

Lastly, a third use for AI detection technology relates to the detection of psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease, all of which may benefit the individual when detected early. With an aging population, this could be a massive market and for anyone with loved ones who suffer from any of these disorders, you know the importance of early detection.

In keeping with the company’s screening focus, in 2020 Predictmedix acquired Mobile Wellbeing, a telemedicine remote patient monitoring platform that will integrate with Predictmedix’s AI driven rapid screening system for infectious diseases. According to the company, Mobile Wellbeing has demonstrated its value in multiple different programs over several years, and has shown benefits such as improved patient health, minimized the impact of chronic disease, and driven down the cost for care through remote monitoring.

With an inherent demand for quick, effective and non-invasive detection technologies, Predictmedix is in a very desirable market with an industry leading product. While the company share price has fallen dramatically from the July 2020 high of $1.13, watch for significant business progress and announcements that could reverse this share price trajectory. The Safe Entry System (and others like it) are soon going to become as common as automatic door openers and could be deployed anywhere there is a large movement of people. The market potential is huge – don’t miss it!

Innovative Predictiv AI products ThermalPass and Alertfleet hit the commercialization phase

Imagine if you could predict the future. The implications are enormous across so many areas from finance, technology, health, security, environment etc. Well now there is a way of predicting events by using Artificial Intelligence (AI) and big data analysis. Today’s company offers AI solutions such as mass thermal screening tests to help fight against COVID-19 and AI software to predict/forecast the weather up to 72-hours in advance to help with safety and economics of fleets.

Predictiv AI Inc. (TSXV: PAI) (‘Predictiv’) is a cutting edge technology company which helps businesses and organizations make smarter decisions using advanced AI, deep machine learning, and data science techniques.

Predictiv’s main initial focus is on commercializing their technology across ‘smart cities’ in areas such as public safety, energy management, smart buildings, mobility, technology, infrastructure, and healthcare sectors.

Predictiv state that the AI potential of the above areas of the smart cities market is potentially worth as much as US$1.56 trillion by 2025. Of course if you can predict future outcomes using AI then the world is your oyster. As investors of the stock market know automated ‘quant’ or algorithmic trading is rapidly growing in popularity and could be worth as much as US$18.8 billion pa in revenues by 2024. AI is already succeeding in the stock market and perhaps soon in the lucrative robotaxi/autonomous vehicle market (aka Tesla (NASDAQ: TSLA)).

Predictiv’s two wholly-owned subsidiaries focus on the public safety opportunity

AI Labs Inc.

AI Labs is the research and development business arm of Predictiv. AI Labs designed, engineered and developed ThermalPass™, a fever detection system approved by Health Canada, to mitigate the spread of contagions in public places.

AI Labs plans to commercialize ThermalPass™ under SMRT Labs Inc., offering two offerings, the ThermalPass Portable (US $6,900) and ThermalPass Pro (US $7,300). As of Jan. 5, 2021 Predictiv reports that they have received orders for 62 units of ThermalPass following the commercial launch in mid-October 2020, including initial orders from hospitals, long-term care facilities and prisons in Canada, as well as hospitals and public schools in the US.

A recent commercialization deal was made with TFG Concepts to represent ThermalPass to its clients across Canada.

Predictiv’s subsidiary AI Labs owned ThermalPass™ for mass public temperature screening – Highly useful in the fight against COVID-19

Source: Company presentation

Weather Telematics Inc.

Weather Telematics Inc. provides ground truth weather. Through its’ patented AI and sensor technology, the Company is able to provide up to 72-hours advance proprietary predictive weather data to sectors including government, insurance, agriculture, public safety and fleet management.

Weather Telematics has developed ‘Alert Fleet’, a cost-saving software/sensor system that provides fleet owners with the tools they need to run significantly safer and more efficient fleets.

Weather Telematics has formed a new strategic channel partnership with inField Solutions Inc. to commercialize Alert Fleet. Weather Telematics has already secured a multi-year agreement with Synoptic Data PBC for data provision services. The Company state that “this licensing contract will generate seven-figure revenue over the term for Weather Telematics and will launch its next generation of weather and road temperature sensors, which turns vehicles into their own mobile weather stations.”

Predictiv’s subsidiary Weather Telematics Inc. owned Alert Fleet with weather alerts etc for fleet safety and economics

Source: Company presentation

Michael Lende, President and CEO of Predictiv AI, recently stated:

“Our goals for 2021 are to continue to extend and strengthen our innovative product portfolio, to ramp up sales of ThermalPass and AlertFleet, both internally as well as through strategic channel partners, and to continue targeting whitespace categories and verticals which we view as innately scalable. In 2021, our focus remains on building the business by increasing revenue and driving shareholder value.”

Closing remarks

Generally speaking the best time to jump on board with promising companies is not too early in the invention phase, but rather at the beginning of the commercialization phase, just as revenues are about to hopefully take-off. This is the stage that Predictiv AI is now entering and they have already had some good early success.

Predictiv AI trades on a market cap of only C$13.2 million, therefore it is potentially still very early days for the Company.

I wonder what Predictiv AI’s software forecasts for their stock price in 2021? It certainly looks like it should be an excellent year ahead for Predictiv AI.

Thompson on DIAGNOS and the ‘exploding’ AI healthtech industry

AI Healthcare Provider Diagnos Continues to Sign Deals and Partnerships Amid COVID-19 Crisis

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF | FSE:4D4A), a software platform provider for the early detection of critical health issues through the use of Artificial Intelligence (“AI”) and Machine Learning (“ML”), continues to sign deals and partnerships amid the current COVID-19 health crisis.

Diagnos’ CARA (“Computer Assisted Retina Analysis”) telemedicine platform, delivers eye care and disease diagnosis through standard fundus photography, which involves photographing the rear of an eye, and Diagnos’ patented image processing and AI analysis.

New 3-Year Agreement with University of Montreal Hospital Centre

On January 19, Diagnos announced a three-year partnership agreement with the Center Hospitalier de l’Université de Montréal (“CHUM”) on AI projects related to the early detection of various retinal diseases.

Since 2018, Diagnos has been working with CHUM and using AI to screen for diabetic retinopathy and added a second screening site in the ophthalmology department in 2019 to help improve the screening process for patients with more serious conditions.

The new 3-year clinical trial aims to validate if the AI algorithm (“NeoRetina”) developed by Diagnos to detect the presence of diabetic retinopathy, can detect this disease and grade its severity by the analysis of fundus photographs when compared with traditional methods.

According to the clinical trial information, more than 10% of the population of Quebec (approximately 900,000 people), suffer from diabetes and around 40% of people with diabetes suffer from diabetic retinopathy.

Retinopathy is any damage to the retina of the eyes, which may cause vision impairment, and early detection and regular check-ups are important in preventing the progression of the disease.

Dr. Fabrice Brunet, President and CEO of CHUM, commented, “We are pleased to be working with Diagnos to bring innovation and excellence in care to patients. The evaluation and refinement of Diagnos technology using artificial intelligence in the early detection of certain diseases by our ophthalmology, endocrinology, and now cardiology teams contribute to improving the quality and safety of the care provided to the population.”

New Clinics in Saudi Arabia and New Rollouts Planned in Second Half of 2021

On January 14, Diagnos announced the opening of five new screening clinics at different locations of Magrabi Hospitals & Centers located in Riyadh, Saudi Arabia, with the help of its Saudi business partner, Kanhoor Medical Co.

Magrabi is a provider of Ears-Nose-and-Throat (“ENT”), Dentistry, and Ophthalmology services with more than 35 locations in the Middle East and North Africa and delivers eye care to more than 1 million patients annually.

After 2 field trials using Diagnos’ AI-assisted screening platform, Magrabi is launching the new locations to increase the availability of the CARA service to its diabetic patients and also to reduce wait times.

The plan between Diagnos, Magrabi, and Kanhoor is to rollout the CARA platform to the remaining 22 Magrabi hospitals in Saudi Arabia in the second half of 2021 and then extend the service to the other Magrabi hospitals in the Middle East and Africa.

Healthcare Diagnosis Market Exploding

According to a 2020 industry report on the Healthcare Diagnosis market, AI in the healthcare diagnosis market was valued at US$3.6 billion in 2019 and is forecasted to reach US$66.8 billion by 2027, growing by a staggering 44% annually.

One of the largest growth segments is AI-assisted diagnostic solutions in areas such as cancer detection, cardiovascular disease, eye care, and radiology.

Worldwide Commercialization

Diagnos currently operates screening sites in 15 countries with certifications from regulatory bodies in various countries including the U.S., Canada, the European Union, and Mexico. In 2020, Diagnos signed partnerships and commercial agreements with companies that serve patients in Canada, Colombia, Guatemala, Mexico, and southern California.

Final Comments

In a recent interview, Andre Larente, CEO of Diagnos, commented that the company is fully funded for the next 18 months and he expects that more existing clients are going to restart their operations soon, which should increase revenue for Diagnos.

In addition, he said the company has a “strong pipeline” that could results in new deal announcements during the year.

Finally, screening for diabetic retinopathy is just one application of Diagnos’ AI technology and the company expects to make announcements with new partners to use the technology to detect other health issues, such as cardiovascular problems, including hypertension.

Meanwhile, even after Diagnos’ recent stock increase, the company’s market capitalization is less than C$43 million. With its recent announcements and rollout trajectory, the low valuation makes it a prime takeover target for any consolidator executing a roll-up strategy in the AI healthtech industry.

Perimeter Medical Imaging AI is potentially disrupting post cancer surgery imaging with a goal to help save lives, costs, and time

Any technology that can help us beat cancer is most welcome. One company is developing a revolutionary way for surgeons to better assess if they have removed all the cancer, all while still in the operating room. This same company was recently recognized as one of the “10 most promising companies” at the Texas Life Science Forum.

The company is Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (‘Perimeter’). The AI in their name refers to the fact that they use Artificial Intelligence (AI) in addition to their imaging technology. A combination of imaging and AI helps surgeons identify if cancer is still present post-tumor removal surgery by examining the ‘perimeter’ of the excised area, hence the company name.

Perimeter’s goal as a medical technology company is to transform cancer surgery with advanced, real-time, ultra-high-resolution imaging tools to address areas of high unmet medical need. Perimeter’s OTIS™ platform is an FDA-cleared point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen.

Perimeter’s OTIS™ (Optical Tissue Imaging System) is FDA cleared point-of-care imaging system for use in real time clinical procedures


Cancer left behind after surgery is a significant problem

As we all know cancer surgery does not always get all the cancer. For example, breast lumpectomy surgeries currently face 25% re-operation rates. This is not ideal for the patient and it is not ideal for the health care system. Re-operating costs are, on average, $16,000 to cover the additional hospital cost per patient, which when added up, amounts to an additional $560 million annual cost to the U.S. healthcare system.

The best solution for all parties is to be able to do point-of-care real time imaging using Perimeter’s Optical Tissue Imaging System (OTIS) taking only 10 minutes to do. By contrast the current standard way is to send off a post-operative histology tissue sample for assessment, which takes 2 to 7 days. Now that’s a potential disruption right there.

Perimeter’s commercialization strategy

Perimeter currently uses their OTIS device in limited markets but have plans to expand, with an initial focus in the US on post surgery breast cancer imaging. According to Perimeter (and WHO projections) the total addressable market across all areas for Perimeter is US$3.7 billion.


To get a feel for the initial ‘revenue potential’ just from targeting US breast cancer lumpectomy cases only, Perimeter prepared the slide below. It shows based on a mid case scenario of 500 hospitals doing 3 imaging procedures per week at $750 each, perimeter’s potential revenue could reach $56.3 million pa of recurring revenue. This is just theoretical at this stage, but shows the potential revenues from just one type of post cancer surgery (post breast cancer lumpectomy). In time Perimeter would aim to expand to many types of cancer post surgery imaging.

Perimeter’s ‘target potential’ revenue only from breast lumpectomy post-surgery imaging


Perimeter’s Q3 2020 financial results were reported here.

Closing remarks

Perimeter Medical Imaging AI is potentially disrupting post cancer surgery imaging with a goal to help save lives, costs, and time. Perimeter’s OTIS™ is already FDA cleared; however there is still some further next stage product development ongoing in the area of training the computer (AI training), as well as further studies. Perimeter is targeting a limited market release in Q1 2021 and a broader commercial launch in Q2 2021.

Perimeter’s board and management team are extremely experienced and highly credentialed. The company is rapidly gaining recognition and now has a market cap of C$87 million after only listing on the TSX-V in mid 2020. It is certainly looking like 2021 will be a breakthrough year for Perimeter Medical Imaging AI. Stay tuned.

Disclosure: The author is long Perimeter Medical Imaging AI, Inc. (TSXV: PINK)

Brendon Grunewald of Moovly Media talks about why video content creation is king during Covid and beyond

In a recent InvestorIntel interview Peter Clausi speaks with Brendon Grunewald, Co-Founder and CEO of Moovly Media Inc. (TSXV: MVY) about recent advances in Moovly’s video content publishing platform.

“One silver lining to the pandemic is people having to discover new ways of learning and working, and video is becoming an essential part of that,” Brendon said. “I believe that’s not just related to Covid, but that is part of a long-term trend.”

Moovly has also taken advantage of the lockdown by adding new features to their already robust and feature-rich online video content creation platform. “Many of these new features are client-driven,” Brendon said, “particularly clients in the corporate enterprise space and education.”

The ability of users to create templates and upload and publish videos instantly “is a feature particularly appreciated by bigger organizations because they may have graphics specialists in their headquarters, but not everyone is a graphics specialist,” he continued. This allows a company to create a template “and then anyone in the field who can drive a mouse and a keyboard can actually adapt and customize it and make themselves look like content geniuses.”

One of the new features is the ability to transform PowerPoint presentations into video, adding music and other video elements from Moovly’s extensive royalty-free library. “A lot of companies have amassed a sizeable number of PowerPoint presentations,” Brendon said, “and what they are looking to do is make them more engaging, particularly to the younger generation.” Brendon explains how the Moovly tool takes all the elements of each PowerPoint slide, including graphics and transitions, and automatically converts them to video. It automates the process and “saves a lot of time, which is its primary value.”

Last month Moovly also announced that it had integrated Google Translate into its platform, allowing for instant sub-titles for videos into more than 100 languages. Brendon told Peter that this is particularly valuable to multinational companies that need to have content translated and localized for multiple markets.

With over 3 million users, Brendon said that “our key value proposition is that we are trying to democratize the ability for everyone to really make high-end content.” And whether you are a big or small business, an individual, or an educator, Moovly, he continued, “really gives the tools to people to really make content with the click of a button.”

To watch the full interview, click here.

Click here to subscribe to the InvestorIntel Channel.

Disclaimer: Moovly Media Inc., Inc. is an advertorial member of InvestorIntel Corp.

Diagnos’ Andre Larente on the benefits of using AI for the early detection of critical health issues

“Our (AI) technology works, its in production (CARA). We are fully funded….the markets we are going after are extremely big…” are excerpts that Andre Larente of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) offered Tracy Weslosky of InvestorIntel in a recent interview.

Tracy starts the interview by identifying the increasing interest from the global market on the Canadian biotech sector. She asks Andre to identify their competitive advantages for investors seeking to understand this market better. Andre explains “we specialize in using AI to tackle some of the medical imaging issues in the world.”

Click here to hear the full interview and learn more about how Diagnos offers early detection medical tests for a wide spectrum of critical medical issues that range from diabetes to cardiovascular issues.

About Diagnos:

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.